New pill may keep rare lymphoma in check after chemo

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed written informed consent prior to any study-specific procedures and willingness to comply with all study requirements. * Age ≥18 years at the time of informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 without deterioration within 2 weeks before screening. * Histologically confirmed PTCL according to the 2016 WHO classification, limited to the following subtypes: PTCL-not otherwise specified (excluding primary cutaneous PTCL), ALK-positive anaplastic large cell lymphoma (ALK-ALCL), angioimmunoblastic T-cell lymphoma (AITL), or T-follicular helper phenotype PTCL (FTCL or PTCL-TFH). * Achieved complete response (CR) or partial response (PR) after first-line systemic standard chemotherapy with CHOP, BV-CHP, or CHOP-like regimens, as assessed by Lugano 2014 criteria; patients must be ineligible for HSCT (age \>65 years) or eligible but decline HSCT (age ≤65 years). The interval between completion of first-line therapy and planned first dose in this study must be ≤3 months. * Adequate bone marrow and organ function, including: * Absolute neutrophil count (ANC) ≥1.5×10⁹/L (≥1.0×10⁹/L if bone marrow is involved by lymphoma), without use of colony-stimulating factors within 7 days before study entry. * Platelet count ≥100×10⁹/L (≥75×10⁹/L if bone marrow is involved by lymphoma), without transfusion or platelet growth factors within 7 days before study entry. * Hemoglobin ≥10 g/dL. * Total bilirubin ≤2× upper limit of normal (ULN). * ALT and AST ≤2.5×ULN. * Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min (calculated or measured). * Left ventricular ejection fraction (LVEF) ≥50% on echocardiography. * Willingness and ability to comply with study procedures and follow-up. Exclusion Criteria: * Ann Arbor stage I disease at initial diagnosis. * Prior treatments that could interfere with study therapy, including but not limited to: * Investigational agents or antineoplastic drugs within 30 days before first study dose. * Cytotoxic chemotherapy within 21 days before first study dose. * Systemic corticosteroids at a prednisone-equivalent dose \>10 mg/day within 7 days before first study dose. * Major surgery (excluding vascular access procedures) or severe trauma within 4 weeks before first study dose, or planned surgery during study treatment. * Antineoplastic monoclonal antibodies (including brentuximab vedotin) within 4 weeks before first study dose; radiotherapy within 3 weeks; other toxin- or radioisotope-conjugated antibodies within 10 weeks. * Prior treatment with any JAK or STAT3 inhibitor. * Antitumor immunotherapy (e.g., immune checkpoint inhibitors including PD-1, PD-L1, CTLA-4 antibodies) within 28 days before first study dose. * Live attenuated or viral vector vaccines within 28 days before first study dose. * Current use of vitamin K antagonists, antiplatelet or anticoagulant drugs that cannot be discontinued ≥7 days before first study dose. * Concomitant medications that are strong CYP3A inducers or inhibitors, or BCRP/P-gp substrates with narrow therapeutic index that cannot be stopped ≥7 days before first study dose, as specified in the protocol appendix. * Active hepatitis C infection (positive anti-HCV antibody). * Hepatitis B virus (HBV) DNA ≥1000 IU/mL or other HBV status not meeting protocol-defined criteria for safe inclusion. * Known HIV infection with confirmed positive serology. * Any uncontrolled, clinically significant comorbidities or laboratory abnormalities that, in the investigator's judgment, would increase risk or interfere with study participation. * History of drug-induced interstitial lung disease or current evidence of clinically significant interstitial lung disease. * Pregnant or breastfeeding women; women of childbearing potential and men with fertile partners who are unwilling or unable to use effective contraception during treatment and for the protocol-specified period after the last dose.